336 related articles for article (PubMed ID: 15598967)
1. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
Li C; Du X; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2007 May; 51(5):1725-30. PubMed ID: 17307978
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
10. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
11. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
Ariano RE; Zelenitsky SA; Nyhlén A; Sitar DS
J Clin Pharmacol; 2005 Jul; 45(7):832-5. PubMed ID: 15951473
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau DP
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
[TBL] [Abstract][Full Text] [Related]
14. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Nomura K; Morikawa N; Ikawa K; Ikeda K; Fujimoto Y; Shimizu D; Taniguchi K; Shimura K; Kanbayashi Y; Komori T; Matsumoto Y; Fujita N; Shimazaki C; Taniwaki M
J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
McKinnon PS; Paladino JA; Schentag JJ
Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
[TBL] [Abstract][Full Text] [Related]
18. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
Chayakulkeeree M; Thamlikitkul V
J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
[TBL] [Abstract][Full Text] [Related]
19. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
20. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
